Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen.
The renin-angiotensin system plays an important role in blood pressure regulation. Angiotensinogen, which is mainly produced in the liver, is a unique component of the renin-angiotensin system, because angiotensinogen is only known as a substrate for angiotensin I generation. It is unclear whether circulating angiotensinogen is a rate-limiting step in blood pressure regulation. Recent findings of genetic studies and analyses suggest that the angiotensinogen gene may be a candidate as a determinant of hypertension. To test the hypothesis that angiotensinogen may modulate blood pressure, we transfected antisense oligonucleotides against rat angiotensinogen into the rat liver via the portal vein using liposomes that contain viral agglutinins to promote fusion with target cells, a technique that has been reported to be highly efficient. Transfection of antisense oligonucleotides resulted in a transient decrease in plasma angiotensinogen levels in spontaneously hypertensive rats from day 1 to day 7 after the injection, consistent with the reduction of hepatic angiotensinogen mRNA. Plasma angiotensin II concentration was also decreased in rats transfected with antisense oligonucleotides. Moreover, a transient decrease in blood pressure from day 1 to day 4 was observed, whereas transfection of sense and scrambled oligonucleotides did not result in any changes in plasma angiotensinogen level, blood pressure, or angiotensinogen mRNA level. Overall, our results demonstrate that transfection of antisense oligonucleotides against rat angiotensinogen resulted in a transient decrease in the high blood pressure of spontaneously hypertensive rats, accompanied by a decrease in angiotensinogen and angiotensin II levels.(ABSTRACT TRUNCATED AT 250 WORDS)
Tomita
N
N
Department of Geriatric Medicine, Osaka (Japan) University Medical School.
Morishita
R
R
Higaki
J
J
Aoki
M
M
Nakamura
Y
Y
Mikami
H
H
Fukamizu
A
A
Murakami
K
K
Kaneda
Y
Y
Ogihara
T
T
D000704:Analysis of Variance; D000804:Angiotensin II / Q000097:blood; D000808:Angiotensinogen / Q000032:analysis / Q000097:blood / Q000235:genetics*; D000818:Animals; D001794:Blood Pressure; D002478:Cells, Cultured; D018076:DNA, Complementary / Q000032:analysis; D015316:Genetic Therapy; D006973:Hypertension / Q000097:blood / Q000235:genetics* / Q000628:therapy; D008099:Liver / Q000737:chemistry / Q000166:cytology; D008297:Male; D016376:Oligonucleotides, Antisense / Q000235:genetics*; D010222:Parainfluenza Virus 1, Human / Q000235:genetics*; D012313:RNA / Q000032:analysis; D011863:Radioimmunoassay; D051381:Rats; D011918:Rats, Inbred SHR; D017208:Rats, Wistar; D013997:Time Factors; D014162:Transfection
D018076:DNA, Complementary; D016376:Oligonucleotides, Antisense; D000808:Angiotensinogen; D000804:Angiotensin II; D012313:RNA